Last reviewed · How we verify

RO7234292 — Competitive Intelligence Brief

RO7234292 (RO7234292) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (CLDN18.2-targeting). Area: Oncology.

phase 3 Monoclonal antibody (CLDN18.2-targeting) Claudin 18.2 (CLDN18.2) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

RO7234292 (RO7234292) — Hoffmann-La Roche. RO7234292 is a monoclonal antibody that targets and inhibits Claudin 18.2 (CLDN18.2), a tumor-associated antigen expressed on gastric and other cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
RO7234292 TARGET RO7234292 Hoffmann-La Roche phase 3 Monoclonal antibody (CLDN18.2-targeting) Claudin 18.2 (CLDN18.2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (CLDN18.2-targeting) class)

  1. Hoffmann-La Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RO7234292 — Competitive Intelligence Brief. https://druglandscape.com/ci/ro7234292. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: